Endothelial Cell Loss After Cataract Surgery
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00932191 |
Recruitment Status
:
Terminated
(Stopped for lack of funds)
First Posted
: July 3, 2009
Last Update Posted
: August 25, 2014
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Cataracts | Procedure: Standard phacoemulsification Procedure: Reduced ultrasound phacoemulsification | Phase 2 Phase 3 |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 39 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | Single (Participant) |
Primary Purpose: | Treatment |
Official Title: | Endothelial Cell Loss After Cataract Surgery: Comparison of a Reduced Ultrasound Technique Versus Standard Ultrasound Technique |
Study Start Date : | July 2009 |
Actual Primary Completion Date : | July 2012 |
Actual Study Completion Date : | July 2012 |
Arm | Intervention/treatment |
---|---|
Active Comparator: Ultrasound phacoemulsification
Cataract nucleus is removed using standard amounts of ultrasound energy.
|
Procedure: Standard phacoemulsification
Cataract nucleus removal using standard amounts of ultrasound energy
|
Active Comparator: Reduced ultrasound phacoemulsification
Cataract nucleus removal using less ultrasound energy and more mechanical energy.
|
Procedure: Reduced ultrasound phacoemulsification
Cataract nucleus removal using less ultrasound energy and more mechanical energy.
|
- Corneal endothelial cell loss by specular microscopy after cataract surgery [ Time Frame: 3 months post-operatively ]

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 40 Years and older (Adult, Senior) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Visually significant moderate density cataract
Exclusion Criteria:
- Corneal or retinal pathology limiting visual potential to worse than 20/40
- Lens pathology including pseudoexfoliation or lens dislocation
- Prior intraocular surgery
- Age less than 40

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00932191
United States, California | |
University of California San Francisco | |
San Francisco, California, United States, 94143 |
Principal Investigator: | David Hwang, MD | University of California, San Francisco |
Responsible Party: | University of California, San Francisco |
ClinicalTrials.gov Identifier: | NCT00932191 History of Changes |
Other Study ID Numbers: |
DHCrush001 |
First Posted: | July 3, 2009 Key Record Dates |
Last Update Posted: | August 25, 2014 |
Last Verified: | August 2014 |
Keywords provided by University of California, San Francisco:
Cataract Corneal endothelial cell loss Ultrasound power Corneal endothelium |
Additional relevant MeSH terms:
Cataract Capsule Opacification Lens Diseases Eye Diseases |